Published 09/27/2023 9:20:03 a.m.

Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

Summary by Medical Xpress

A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine. By providing whole-body quantification of HER2 expression, 68Ga-ABY-025 PET/CT can play a valuable role in treatment planning and could spare patients from unnecessary drug-related si…

0 Articles

All

Left

Center

Right

Medical Xpress

Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

09/27/2023 9:20:03 a.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated09/27/2023 1:59:38 p.m.Bias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

0 Articles

0 Articles

Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics